Welcome to our dedicated page for Cabbacis news (Ticker: CABI), a resource for investors and traders seeking the latest updates and insights on Cabbacis stock.
Cabbacis Inc. develops tobacco risk-reduction products under the iBlend™ brand as a federally licensed tobacco-product manufacturer. Company news centers on iBlend™ cigarettes and vaporizer pods that combine very-low-nicotine tobacco with hemp, along with product-development updates, reported clinical work, intellectual-property activity and preparation for FDA Premarket Tobacco Product Application submissions.
Recurring updates also cover Regulation A financing activity, corporate presentations, commercialization planning and the company’s patent portfolio for tobacco-hemp combinations in cigarettes and vaporizer pods across major tobacco markets.
Cabbacis (OTCQB:CABI) will participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on June 3-4, 2026. CEO Joseph Pandolfino will host virtual one-on-one meetings and a webcast presentation on Thursday, June 4, 2026, from 11:00-11:25 a.m. ET.
The virtual event will be accessible via online webcast, with registration required for participation.
Cabbacis (OTCQB:CABI), a U.S. federally licensed tobacco-product manufacturer focused on patented risk-reduction products under the iBLEND™ brand, will participate in the Sidoti Micro-Cap Virtual Conference on May 20-21, 2026.
CEO Joseph Pandolfino will host virtual one-on-one investor meetings and a webcast presentation on May 21, 2026, from 10:00-10:30 a.m. Eastern Time. Attendance is virtual only with mandatory registration via the Sidoti Zoom link.
Cabbacis (OTCQB: CABI) filed its Form 1-K for fiscal 2025 reporting a net loss of $1,582,821 and basic/diluted EPS of ($0.24). Cash used in operations was $1,177,842, and the company recorded no revenue in 2025. The company reported positive clinical and consumer testing for its iBLEND™ very-low-nicotine cigarettes, strengthened its patent portfolio to 36 issued patents, and launched a Regulation A offering to raise up to $7.5 million (approximately $1.2 million subscribed to date). A ~60-smoker study starts Q2 2026 and the company targets filing a PMTA by January 2027.
Cabbacis (OTCQB: CABI) announced management will present at the Noble Emerging Growth Virtual Equity Conference on February 4-5, 2026. CEO Joseph Pandolfino will present on Feb 4, 2026 at 11:00 a.m. ET and hold one-on-one investor meetings. Registration is required and the presentation is webcast.
The company said its $7.5 million Regulation A+ offering is progressing and highlighted a global patent portfolio of 36 issued patents (including 8 U.S.) for its iBlend brand as it advances product development and planned international rollout later in 2026.
Cabbacis (OTCQB: CABI) issued a shareholder letter outlining 2025 milestones and 2026 plans for its iBlend very-low-nicotine tobacco products. Highlights include positive pilot clinical results, a global patent portfolio of 36 patents, a clean balance sheet, a SEC-qualified Regulation A+ offering, and a planned PMTA filing mid-2026.
The company targets limited international rollouts in late 2026, two follow-up behavioral studies in early 2026, and a U.S. PMTA review timeline the company anticipates could be about one year.
Cabbacis (OTCQB: CABI) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,527,346 for vaporizer pods combining reconstituted tobacco and reconstituted hemp (CBGA-most abundant); the patent expires January 1, 2039 and includes seven claims. The company noted this patent complements three previously issued U.S. patents (10,777,091; 10,973,255; 12,349,724) and international patents, and said its products are patented across more than 30 countries.
Cabbacis (OTCQB: CABI) announced a $7.5 million Regulation A offering and will host an investor webinar on January 22, 2026 at 11:30 AM ET. CEO Joseph Pandolfino will discuss investment details, the development and commercialization of the company’s patented iBlend™ cigarettes and vaporizer pods (very-low-nicotine tobacco plus hemp), the company’s FDA path for U.S. commercialization, and an international rollout expected later in 2026 to generate early revenue and brand validation. The webinar replay will be emailed to registrants; investors are not required to be accredited.
Summary not available.
Cabbacis (OTCQB: CABI), a tobacco-product manufacturer, released its First Half 2025 corporate update. The company reported a net loss of $735,560 ($0.12 per share), compared to a loss of $299,480 ($0.05 per share) in H1 2024, with no revenue in both periods.
Key developments include successful clinical trials of their iBlend™ cigarettes, expansion of their patent portfolio to 35 issued patents, and the launch of a $7.5 million Regulation A offering. The company's clinical trials demonstrated high satisfaction rates and reduced cravings, with their products containing approximately 95% less nicotine than mainstream brands.
Cabbacis plans to file its first PMTA around January 2026 and is exploring international licensing opportunities while awaiting FDA review.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer, will participate in the upcoming Q3 Virtual Investor Summit on September 16-17, 2025. CEO Joseph Pandolfino will present on Tuesday, September 16, at 10:00 a.m. Eastern time and conduct one-on-one meetings with institutional investors.
The company will discuss recent achievements, including the granting of U.S. patent No. 12,349,724 for their vaporizer pods and the qualification of their Regulation A Tier 2 offering. These developments support Cabbacis's commercialization strategy in the harm-reduction tobacco products sector under their iBlend™ brand.